Key Insights

Highlights

Treatment Research

3 treatments under study, led by Fludarabine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05963217Phase 1RecruitingPrimary

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Showing all 1 trials

Research Network

Common Treatments

  • Fludarabine1
  • Cyclophosphamide1
  • Tbi20011

Active Sponsors

  • Takara Bio Inc.1
  • University Health Network, Toronto1

Top Investigators

Related Conditions

  • Relapsed Or Refractory Chronic Lymphocytic Leukemia1
  • Relapsed Or Refractory Small Lymphocytic Lymphoma1

Activity Timeline